Hikma Pharmaceuticals – Equity Research
With a huge decline in price over 2017, it is only right that we update our research on Hikma Pharmaceuticals and share it with you all!
Hikma Pharmaceuticals is a FTSE250 company that focuses on developing, manufacturing and marketing pharmaceutical products in the US, Middle East, North Africa and Europe. Over 2017, unimpressive results and failed new drug applications have really stung Hikma Pharmaceuticals share price.
Using our analysis methodology, we have put together an equity research sheet on Hikma. Has this price drop presented an opportunity to pick up a top pharmaceutical company at an amazing price?
Download our research sheet now to find out whether we regard Hikma Pharmaceuticals as one of the best stocks to buy!